塞利尼索在伴 del17p 及其他高危异常的复发/难治性多发性骨髓瘤（RRMM）患者中的疗效（一项回顾性单中心研究）

Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein, exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which increases nuclear retention of tumor suppressor proteins (TSPs), including p53, thereby limiting the translation of oncogenes, triggering cell cycle arrest and the death of malignant cells. Multiple Myeloma (MM) patients with del17p are deficient in TP53 and have a particularly poor prognosis.

Given its unique mechanism of action, we investigated whether Seli has increased efficacy in RRMM patients with del17p compared to other high-risk cytogenetics (OHRC). This is an IRB-approved observational study of RRMM patients with high-risk cytogenetics (del17p, t (4;14), t (14;16) or gain 1q) or standard-risk cytogenetics treated at the Levine Cancer Institute (LCI) with a Seli-based regimen between January 2019 and December 2022.

Time-to-event endpoints (PFS, OS) were evaluated using Kaplan-Meier (KM) methods. Log-rank tests compared time-to-event endpoints between cohorts [del17p vs. OHRC vs. standard risk].

We identified 40 RRMM patients with high-risk cytogenetics, including 16 patients with del17p and 24 patients with OHRC, as well as 20 with standard-risk cytogenetics. The median age was 62. 5 vs. 69 vs. 65. 5 years (del17p group vs. OHRC vs. standard risk). The median prior line of therapies was five (range: 3-16) with similar rates of prior autologous stem cell transplant in all arms (68. 8% vs. 62. 5% vs. 70. 0%). The most frequently used regimens were Seli-Pomalidomide-dexamethasone(dex) or Seli-Carfilzomib-dex (Seli-Kd) in the del17p group and Seli-Kd in the OHRC and standard-risk groups. The median time to start the Seli-based regimen after initial MM diagnosis was 5. 6 years for the del17p group, 4.

1 years in OHRC, and 4. 8 years in the standard-risk group. The median follow-up time after the start of the Seli-based regimen was 10. 5 months (mos) in the del17p group, 8. 4 mos in OHRC, and 10. 3 mos in the standard-risk group. In the del17p group, 50% had an objective response, 41. 7% in the OHRC, and 35% in the standard-risk group ( p = 0. 71).

Depth of response was also similar across the arms (12. 5% vs. 12. 5% vs. 10. 0% VGPR p = 0. 99). The median OS was 10. 9 mos in the del17p group, 10. 3 mos in the OHRC, and 10. 3 mos in the standard-risk group ( p = 0. 92). The median OS was 15. 5 mos for patients who received Seli as a bridging therapy versus 9 mos for Seli use for other reasons rather than as a bridge.

Overall, Seli-based regimens showed promising responses even in this heavily pretreated population.

Our analysis suggests that Seli-based regimens lead to similar outcomes among RRMM patients with del17p, OHRC, and standard-risk cytogenetics. This contrasts with previously reported outcomes using combinations of novel therapies in this population, where the del17p patients often have a poorer prognosis. Interestingly, our data suggest that Seli is a particularly effective bridging modality for patients preparing for CAR-T cell therapies in our population.

Further investigation into this population is warranted, including in earlier lines of therapy, in hopes of seeing a more durable response.